You're building out your company's drug testing program, and you've landed on the 5-panel drug test as your starting point. Good instinct. It's the most widely used drug screening panel among both government agencies and private employers in the United States. But here's where it gets complicated: choosing the right panel is only the first decision. You still need to understand what substances are covered, how cutoff levels work, what detection windows mean for your testing timeline, and how state and federal regulations shape your policies. Get any of those wrong, and you're looking at compliance gaps, disputed results, or worse, a preventable workplace safety incident.
Disclaimer: This content is provided for informational purposes only and should not be construed as legal advice. Employers should consult qualified counsel for their specific situation.
This guide breaks down everything HR professionals and safety officers need to know about the standard 5-panel screening in 2026, from the specific substances screened to the practical steps for building a compliant, defensible testing program.
The 5-panel drug test has been the backbone of workplace drug screening since the federal government established its drug-free workplace requirements in the late 1980s. According to the Substance Abuse and Mental Health Services Administration (SAMHSA): federal workplace drug testing standards, the 5-panel urine drug test remains the standard for federally mandated testing programs. Private employers have widely adopted the same panel because it covers the substance categories most commonly associated with workplace impairment and safety risk.
A urine drug test only detects past drug use within a defined detection window. It cannot determine whether a person is currently impaired or unfit for duty at the time of the test.
This is explicitly acknowledged in toxicology literature and federal guidance:
Workplace urine testing (including THC‑COOH testing) does not document impairment or even recent use, particularly for marijuana. It detects inactive metabolites that may remain long after psychoactive effects have ended.
The American Society of Addiction Medicine (ASAM), whose guidance is referenced by SAMHSA, states that drug tests measure the presence of substances within a window of time, not functional or cognitive impairment.
DOT regulations themselves make no claim that urine testing measures impairment; instead, they rely on reasonable suspicion observations and post‑accident context to address impairment concerns.
A 5-panel drug test is a screening that analyzes a biological specimen for the presence of five categories of controlled substances. The specimen is most commonly urine, though hair, saliva, and blood can also be used depending on the employer's needs and applicable regulations.
The test works in two stages. The initial screen uses immunoassay technology to flag specimens that exceed established cutoff concentrations. Any specimen that screens positive at the initial stage is then sent for confirmatory testing, typically using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). This two-step process is designed to minimize false positives and give employers confidence in reported results.
This screening is used across virtually every industry, from office environments conducting pre-employment screens to construction firms running random testing programs. It's also the specific panel required by the U.S. Department of Transportation (DOT): 5-panel drug test requirements for safety-sensitive positions, which we'll cover in more detail below.
The five substance categories on a standard panel are:
Pro Tip: If your industry involves exposure to synthetic opioids or if fentanyl is a concern in your region, the standard 5 may not be sufficient. Talk to your screening provider about expanded panels (7-panel, 10-panel, or custom configurations) that add substances relevant to your workforce.
Yes. THC remains a standard component of the 5-panel screening, including the DOT-mandated version. However, the legal landscape around marijuana testing has shifted dramatically. As of early 2026, a growing number of states and municipalities have enacted laws that restrict or prohibit employers from taking adverse employment action based solely on a positive marijuana test for non-safety-sensitive roles.
The Nuance: Federal law still classifies marijuana as a Schedule I controlled substance, and DOT-regulated employers are required to test for it regardless of state law. But for non-DOT employers, the calculus is more complicated. States like California, New York, and Washington have enacted protections for off-duty marijuana use, while others have carved out exceptions for safety-sensitive positions.
The Impact: If you're a multi-state employer, your marijuana testing policy may need to vary by jurisdiction. A blanket "zero tolerance" approach that worked five years ago could now expose you to discrimination claims in certain states. This is exactly the kind of compliance question where working with a knowledgeable screening partner and qualified legal counsel pays dividends.
Not every trace of a substance in a specimen triggers a positive result. Drug tests use established cutoff concentrations to distinguish between a meaningful positive and trace-level presence that could result from incidental exposure or other non-use scenarios. Understanding how cutoffs work is essential for HR professionals who need to explain results, defend policies, and make informed decisions about their testing programs.
A cutoff level is the minimum concentration of a substance (or its metabolite) that must be present in a specimen for the test to be reported as positive. Concentrations below the cutoff are reported as negative, even if some amount of the substance is technically present.
SAMHSA establishes the cutoff levels for federally mandated workplace drug testing programs. For the standard 5 urine screening, the initial immunoassay screen cutoffs are:
|
Substance |
Initial Screen Cutoff |
Confirmatory Cutoff |
|---|---|---|
|
Marijuana (THC-COOH) |
50 ng/mL |
15 ng/mL |
|
Cocaine (Benzoylecgonine) |
150 ng/mL |
100 ng/mL |
|
Opiates (Codeine/Morphine) |
2000 ng/mL |
2000 ng/mL |
|
Amphetamines |
500 ng/mL |
250 ng/mL |
|
PCP |
25 ng/mL |
25 ng/mL |
These cutoffs are based on DOT Rule 49 CFR Part 40. Private employers that are not subject to federal mandates can choose to adopt these same cutoffs or work with their testing laboratory to establish different thresholds, though any deviation from SAMHSA standards should be done carefully and with legal guidance.
Did You Know: Cutoff levels can vary based on the testing method used. Hair, saliva, and blood tests each have their own cutoff concentrations, which are different from urine cutoffs. This means the same individual could test positive on one specimen type and negative on another, depending on the timing of use and the cutoffs applied.
For employers, the practical implications of cutoff levels include:
One of the most common questions HR professionals ask is: how far back does a 5-panel screening go? The answer depends entirely on the specimen type. Each testing method offers a different detection window, and choosing the right one depends on whether you're trying to detect very recent use, establish a pattern of use, or meet a specific regulatory requirement.
The 5-panel urine screening is by far the most common specimen type for workplace testing. It's the only specimen type accepted for DOT-regulated testing, and it offers a practical balance between detection window, cost, and ease of collection. Detection windows are approximate and can vary based on dose, frequency of use, individual metabolism, and test sensitivity.
|
Substance |
Approximate Detection Window |
|---|---|
|
Marijuana (THC) |
3–30 days (varies significantly with frequency of use) |
|
Cocaine |
2–4 days |
|
Opiates |
2–3 days |
|
Amphetamines |
2–4 days |
|
PCP |
7–14 days |
Marijuana has the widest detection range because THC metabolites are fat-soluble and accumulate in the body with repeated use. A single-use event might be detectable for only a few days, while chronic daily use can produce positive results for 30 days or longer after cessation.
Hair testing offers the longest detection window of any specimen type, typically covering approximately 90 days of history. The test analyzes a small hair sample (usually 1.5 inches from the scalp) for drug metabolites incorporated into the hair shaft via the bloodstream.
|
Substance |
Approximate Detection Window |
|---|---|
|
Marijuana (THC) |
Up to 90 days |
|
Cocaine |
Up to 90 days |
|
Opiates |
Up to 90 days |
|
Amphetamines |
Up to 90 days |
|
PCP |
Up to 90 days |
Hair testing is particularly useful for identifying patterns of repeated use, but it has limitations. Hair testing reflects historical drug use patterns and does not indicate current impairment or very recent use. It generally cannot detect use that occurred within the most recent 7 to 10 days (because it takes time for metabolites to grow out of the scalp), and there are ongoing discussions in the scientific community about potential bias related to hair color and texture.
Oral fluid (saliva) testing has gained traction in recent years because of its convenience and its ability to detect very recent use. Blood testing is the most invasive and expensive option and is rarely used for routine workplace screening, though it may be employed in post-accident investigations.
|
Substance |
Saliva Detection Window |
Blood Detection Window |
|---|---|---|
|
Marijuana (THC) |
24–72 hours |
2–12 hours (active THC) |
|
Cocaine |
1–2 days |
12–24 hours |
|
Opiates |
1–3 days |
6–12 hours |
|
Amphetamines |
1–3 days |
12–24 hours |
|
PCP |
1–3 days |
24–48 hours |
Oral fluid testing is especially relevant in states that have moved to restrict marijuana testing based on urine results. Some state laws now specify that employers may only test for active impairment rather than past use, which makes oral fluid's shorter detection window more aligned with legislative intent.
Employers in transportation, aviation, pipeline, rail, and other DOT-regulated industries don't have the luxury of choosing their panel or specimen type. The DOT 5-panel drug test is governed by 49 CFR Part 40, which mandates urine testing for the same five substance categories, using SAMHSA-established cutoff levels, through a DOT-certified laboratory, and with review by a qualified MRO.
The Nuance: DOT testing requirements apply to safety-sensitive employees regardless of state marijuana laws. Even if your company operates in a state where recreational marijuana is legal, any employee subject to DOT testing who tests positive for THC will be removed from safety-sensitive duties.
The Impact: Employers who operate both DOT-regulated and non-regulated positions need to maintain separate, clearly documented policies for each group. Applying DOT standards to non-regulated employees (or failing to apply them to regulated employees) can create compliance problems in either direction.
This is a question that comes up more often than many HR professionals expect. The short answer is that the drug test itself doesn't "detect" fake urine, but the collection and laboratory processes are designed to identify issues with specimen validity.
Laboratories perform specimen validity testing (SVT) on every urine specimen, checking for temperature (at the time of collection), creatinine concentration, specific gravity, pH, and the presence of known adulterants or oxidizing agents. A specimen that falls outside normal human physiological ranges will be reported as "substituted" or "invalid" rather than negative, which triggers further action under most employer policies.
DOT collections have particularly strict protocols: direct observation collections may be required in certain circumstances, and collectors are trained to identify suspicious behavior. For non-DOT employers, working with a screening provider that uses SAMHSA-compliant or equivalent laboratory protocols is the best defense against specimen fraud.
A drug testing program only delivers results if it's designed, implemented, and maintained properly. A poorly constructed program can generate legal exposure, damage employee trust, and produce results that don't hold up under scrutiny.
Drug testing sits at the intersection of workplace safety, employee privacy, and a rapidly changing legal environment. Multi-state employers face particular challenges because drug testing laws vary not only by state but increasingly by city and county.
Key legal considerations include:
Pro Tip: Consult with legal experts who specialize in employment law. A policy that's compliant in Texas may violate employee protections in New York or California.
A drug testing program works best when it's not an isolated HR function but part of a broader commitment to workplace safety. Employees are more likely to accept testing when they understand it as one component of a safety culture that also includes training, hazard prevention, and support resources.
Your drug testing program should connect to your overall safety strategy. This means aligning testing triggers with your safety risk assessment. For example, if your workplace involves heavy machinery, post-accident and reasonable suspicion testing should be non-negotiable components. If your workforce is primarily office-based, pre-employment testing may be sufficient.
Consider pairing your testing program with supervisor training on recognizing signs of impairment and with clear protocols for reasonable suspicion documentation. A supervisor who can articulate specific, observable behaviors that prompted a reasonable suspicion test creates a much stronger defensible record than one who relies on a "gut feeling."
Transparency builds trust. Communicate your drug testing policy during onboarding, include it in your employee handbook, and revisit it during annual safety training. Explain not just the "what" (we test for these substances under these circumstances) but the "why" (we're committed to keeping everyone safe on the job).
When policy changes occur, whether because of a new state law, an updated panel, or a change in testing triggers, communicate those changes proactively and give employees a reasonable window to review and acknowledge the updated policy.
Building and maintaining a compliant drug testing program across multiple states and regulatory frameworks is genuinely complex work. At AccuSourceHR, our PBSA-certified, FCRA-certified team works alongside an in-house counsel-led compliance team to help employers design testing programs that meet both federal and state requirements. Whether you need a standard 5, an expanded panel, DOT-compliant testing, or guidance on navigating marijuana legalization in your operating states, we bring the expertise and the infrastructure to support you.
Our SourceDirect™ platform integrates drug testing orders and results directly into your hiring workflow, with connections to major ATS and HCM systems including Workday, Greenhouse, iCIMS, BambooHR, UKG, and more. And because we believe service matters as much as technology, our 100% US-based support team answers calls live, responds to inquiries within two hours, and works to fully resolve issues within six hours.